Abstract: A storage bag (100) for storing, transporting, freezing, and thawing biopharmaceuticals includes a collapsible pouch (102) including an internal volume and an aperture; a non-collapsible port assembly (114) with a body, a snout (118) extending from the body into the pouch through the aperture, and at least one conduit (120A-C); and a reinforcing laminate (108) surrounding the port assembly and the end of the collapsible pouch including the aperture. At least one peripheral cavity (124A, 124B) is adjacent to a portion of the port assembly and extends from the aperture to at least one conduit so the conduit is in fluid communication with the internal volume through the peripheral cavity. The size of the peripheral cavity can be adjusted to control the volume of fluid trapped between the collapsible pouch and the non-collapsible port assembly, and as such this area advantageously experiences limited expansion during freezing.

Abstract: The present invention relates to a platelet rich plasma (PRP) extracting device and extracting method using the same, and more particularly, to a platelet rich plasma (PRP) extracting device capable of quickly and effectively extracting the highly concentrated PRP from centrifuged blood by a simple manipulation.

Abstract: A syringe that is configured for use in a syringe pump. The syringe has a flange at the proximal end of a barrel and a sealing element at its proximal end. The sealing element has of a disk shaped annular sealing assembly having a hole in its center through which a piston rod passes. The sealing assembly has an upper part and a lower part that are pressed together to hold an O-ring that seals around the piston rod. The sealing assembly is placed inside the barrel of the syringe; thereby not disturbing the external shape of the syringe and allowing the syringe to fit into dedicated grooves on syringe pumps.

Abstract: A system having a syringe and a connector. A proximal end of an outer housing of the connector is a specially designed female Luer element. A distal end of an outer housing of the connector is configured to connect the syringe to a component of a fluid transfer apparatus. The syringe and the connector are configured to be joined together such that they can be swiveled relative to each other around their common longitudinal axis. Once connected together, any attempt to twist the syringe or connector relative to each other in either a counterclockwise direction or a clockwise direction will result in endless swiveling about their common longitudinal axis. In other words, once the system is connected together, the syringe cannot be disconnected from the connector.

Abstract: A supplement dispensing mouthguard device is an apparatus that readily supplies supplements into the mouth of a user while the user is performing an exercise. The apparatus includes an upper U-shaped platform, a lower U-shaped platform, an inner curved wall, an outer curved wall, a main fastener, a supplement reservoir, at least one inlet, and a plurality of outlets. The upper U-shaped platform and the lower U-shaped platform protects the teeth. The inner curved wall and the outer curved wall protects the tongue and the inner walls of the cheeks of the user. The main fastener connects the upper U-shaped platform with the lower U-shaped platform and seals the at least one inlet. The supplement reservoir contains the desired supplement. The at least one inlet provides access into the supplement reservoir. The plurality of outlets distributes the supplement into the mouth of the user.

Abstract: A fluid heating device for on demand heating of fluids for feeding a child includes a pipe that is coupled to and extends from a control module, which comprises a power module. A first and a second tube are coupled to and extend from a first and a second end of the pipe, respectively. A terminus of the first tube is positionable in a reservoir that contains a fluid. A nipple that is coupled to the second tube distal from the pipe is configured to be positioned in a mouth of a child, positioning the child to suck on the nipple to draw the fluid from the reservoir through the first tube into the pipe. A heating element in the pipe heats the fluid as it passes through the pipe. The fluid then passes through the second tube and a hole in the nipple into the mouth of the child.

Abstract: A gastrostomy or nasogastric tube venting unit has a containment vessel for measuring fluids expelled with gastric gas before, during, after, or independent from feeding. The venting unit is particularly well-suited for pediatric or extremely weak patients who have difficulty producing sufficient pressure to expel gas through a fluid-filled feeding tube, including babies weighing less than 2000 grams. The venting unit includes a handle for suspending from an IV pole, a car or infant seat, stroller, a coat hook, or other support structures that might be used for travel. The containment vessel has a splash guard in the form of mesh material or screen covering or molded within the upper opening of the vessel, and can be capped temporarily for ease of transportation. The cap can be reopened when the patient is secured in a car seat or other means for travel, so that venting can resume.

Abstract: A pacifier retention device comprising a tether having a proximal end and a distal end, a housing, a spool with channeled surface, spiral spring, and fasteners attached to the ends of the tether. The proximal and distal ends of the tether are connected to a clothing clip and a loop, respectively. The clip is attached to a piece of clothing while the loop is intertwined with a pacifier, the tether being under constant or configurable tension to prevent unwanted travel of the pacifier when not in use.

Abstract: Disclosed herein are composite materials which may be used as biomedical materials or constructs. The disclosed biomedical materials or constructs may be multiphasic and typically provide a surface for cell growth. The disclosed biomedical materials and constructs typically comprise conjugable and/or adhesive chemical moieties, such as hydroxylated aromatic moieties, which facilitate integration of the components of the biomedical materials and constructs. Suitable hydroxylated aromatic moieties may include dihydroxybenzene (DHB) moieties, such as 1,2-DHB moeities, and derivatives thereof.

Abstract: A solid powder cosmetic is a solid powder cosmetic containing a powder component and an oily component, the contents of the powder component and the oily component are 70% to 95% by mass and 5% to 30% by mass, respectively, based on the total amount of the solid powder cosmetic, and the oily component contains (A) a hardened castor oil fatty acid ester and (B) a heavy liquid isoparaffin.

Abstract: Disclosed are a cosmetic composition and a cosmetic product including the cosmetic composition. The cosmetic composition includes 5 wt % to 30 wt % of a powder, 0.1 wt % to 10 wt % of a film-forming agent, 10 wt % to 30 wt % of a silicone oil, and 0.1 wt % to 10 wt % of a spherical powder.

Abstract: A composition, in particular a cosmetic composition, comprising a fatty phase and an aqueous phase, the aqueous phase being substantially immiscible with the fatty phase, at ambient temperature and atmospheric pressure, wherein: the aqueous phase is in the form of spheres (S1) that are solid at ambient temperature and atmospheric pressure, comprising at least one hydrophilic gelling agent, which is preferably temperature-sensitive, and the fatty phase comprises at least one lipophilic agent having a suspending capacity, which is preferably thixotropic, preferably a hydrophobic silica.

Abstract: Cosmetic compositions for the cosmetic treatment of keratinous fibers, containing, in each case based on their weight: (a) fibers, (b) ethanol, (c) at least one polymer, (d) propellant, (e) from 0 to about 10% by weight of dye(s), (f) from 0 to about 10% by weight of pigment(s), with the proviso that the sum of the amounts of ingredients (e) and (f) is from about 0.0001 to about 10% by weight, to increase the hair volume and cause an increase in the fullness and the feeling of “having more hair”. The coloring of the products also allows coverage of bald areas without causing abrasion on hands or clothing or pillows.

Abstract: The invention provides a thick water-based cosmetic which can impart a novel usage feeling The thick water-based cosmetic of the present invention has a viscoelastic ratio of 10 or more and a viscosity of 500 mPa·s or less at a shear rate of 1/s, wherein when concentrated by a factor of five by drying to remove moisture, the thick water-based cosmetic changes to a gel-like form having a viscoelastic ratio of 0.5 or less and a viscosity of 70000 mPa·s or more at a shear rate of 1/s.

Abstract: A water-in-oil emulsified cosmetic preparation that, even without substantially comprising a UV scattering agent, exhibits a high UV protection effect. This water-in-oil emulsified cosmetic preparation includes: 6%-40% by mass of a UV absorber (A); at least 15% by mass of a non-volatile polar oil component (B) containing an ester bond (and not including the UV absorber (A)); and 0.5%-15% by mass of an oil phase thickener (C). It is particularly preferable that the present invention also includes a powder (D) having an average particle diameter of no more than 15 ?m.

Abstract: Improved high SPF sunscreen formulations not containing oxybenzone and octinoxate are disclosed. The present disclosure also discloses sunscreen compositions including: (i) a film forming component including at least one film forming polymer; (ii) silica; (iii) a sunscreen active component including at least one sunscreen active compound selected from inorganic sunscreen actives, organic sunscreen actives, and combinations thereof; (iv) a carrier; (v) an optional emulsifier component including at least one emulsifier; (vi) an optional emulsion stabilizer component including at least one emulsion stabilizer; (vii) an optional chelator component; and (viii) an optional skin conditioning agent component.

Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. In a separate co-pending application, the invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.

Abstract: The present invention refers to the use of a surface-reacted calcium carbonate having a volume median particle size d50 from 0.1 to 90 ?m as skin appearance modifier in a cosmetic and/or skin care composition.

Abstract: This invention relates to a composition comprising, particularly in a cosmetically acceptable medium: a) at least one aqueous phase; and b) particles with a number-average elementary size greater than 0.1 ?m comprising: i) a perlite matrix, ii) at least one inorganic UV filter, and iii) a silica coating, said silica representing at least 1% by weight relative to the total weight of the composite particle. It also relates to a makeup or treatment process using such a composition.

Abstract: The non-therapeutical, cosmetic use of dihydroxyacetone in a cosmetic composition to be applied on skin, scalp, or hair for the protection of skin, scalp, or hair against infrared irradiation as well as the use of a cosmetic composition containing dihydroxyacetone as an agent for controlling tropoelastin expression in living cells of the epidermis and papillary dermis or as an agent for controlling the degradation of extracellular matrix components in living cells of the epidermis and papillary dermis, and dihydroxyacetone as an active ingredient to protect skin, scalp, or hair against damages after infrared irradiation by reacting with the skin, scalp, or hair or by penetrating the skin, scalp, or hair.

Abstract: The oily solid cleansing cosmetic contains: (A) hydrogenated castor oil, (B) a hydrocarbon-based wax, (C) an ester oil whose viscosity at 25° C. is 50 mPa·s or less, and (D) a nonionic surfactant, wherein the content of the component (A) is 1% to 5% by mass, the content of the component (B) is 1% to 5% by mass, the content of the component (C) is 60% by mass or more, and the total content of the component (A) and the component (B) is 4% to 7.5% by mass.

Abstract: A packaged aerosol foaming skin cleanser can include a multiphase skin cleansing composition, a low pressure foaming agent, and a package.

Abstract: One aspect of the present disclosure is a cosmetic composition containing a solubilized pigment and a method for preparing the same. More specifically, the cosmetic composition containing the solubilized pigment may be prepared through a process of dissolving a pigment in an aqueous phase by dispersing the pigment in the aqueous phase using a pigment dispersing thickener and stabilizing by further increasing the viscosity using a stabilizing thickener. Since the solubilized pigment exhibits dyeing properties similar to dyes, it can be widely applied to various cosmetic compositions.

Abstract: The present invention primarily relates to novel fragrance compositions suitable for enhancing the mood of a subject, preferably a human, novel products containing the same as well as novel uses and methods of such compositions and products.

Abstract: According to the present invention there is provided an aqueous concentrated cosmetic composition comprising at least 20% water, at least 4.5% by weight of the composition of humectant, at least 8% of the composition of a peptide and high levels of a skin benefit active(s).

Abstract: The present invention relates to topical compositions comprising a polysiloxane-based UV filter, hydroxyacetophenone and panthenol, as well as their use in sunscreens.

Abstract: The invention provides an aqueous shampoo composition comprising: a. a pre-formed emulsified silicone; b. a cationic deposition polymer; c. a hair substantive cationic conditioning polymer which is a homopolymer of (3-acrylamidopropyl) trimethyl ammonium chloride; d. a cleansing surfactant; e. a co-surfactant; and f. a suspending agent; which results in superior retention of silicone on hair.

Abstract: A solid or semi-solid water-in-oil type emulsion cosmetic has a hardness that can be balm-like, the cosmetic has an excellent moisturizing effect, exhibiting upon use a unique sensation of blending as if melting when applied to skin, and is capable of stably incorporating a water-soluble or hydrophilic drug. A water-in-oil type emulsion cosmetic contains: (A) an organically modified clay mineral; (B) a surfactant having an HLB of no more than 6; (C) a wax; (D) a silicone elastomer; (E) a volatile oil; and (F) water.

Abstract: A composition for alleviating facial redness containing stem cell-derived exosomes as an active ingredient and a method of reducing facial redness are provided. When a facial skin is treated with the composition for alleviating facial redness containing stem cell-derived exosomes as an active ingredient, the composition exhibits an excellent effect on skin care by reducing the redness of the face and improving the appearance of the face.

Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.

Abstract: Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations.

Abstract: Drug products adapted for nasal delivery comprising naltrexone, alone or in combination with excipients, are provided. Pre-primed devices for intranasal administration of the drug products are also provided.

Abstract: A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area, thereby reducing the amount of wasted medication that would otherwise result from other topical methods. In one embodiment, the medicated gel comprises a sterile viscous gel having a viscosity sufficient to be maintained within a paranasal sinus cavity after insertion, and a medication dispersed in the sterile viscous gel.

Abstract: The present invention provides novel artificial tears containing a recombinant human lysozyme and a recombinant human epidermal growth factor. The novel artificial tears comprise main components and an auxiliary material. The main components are a recombinant human lysozyme, a recombinant human epidermal growth factor, and sodium hyaluronate, wherein the recombinant human lysozyme, the recombinant human epidermal growth factor, and sodium hyaluronate are contained in an amount from 0.075% to 0.300%, from 0.002% to 0.004%, and from 0.10% to 0.30%, respectively in the total mass of the novel artificial tears.

Abstract: The invention is generally related to a soft hydrogel ocular insert that is composed of at least one hydrogel material in fully hydrated state and can be comfortable for wearing. The hydrogel material comprises polymer chains, which are derived from at least one arylborono-containing hydrophilic copolymer and at least one mucoadhesive polymer, and cyclic boronic ester crosslinks for crosslinking those mucoadhesive polymer chains and arylborono-containing hydrophilic copolymer chains to form a 3-dimensional polymer network. Those cyclic boronic ester crosslinks can be hydrolyzed slowly in the tear of the eyes of a patient, resulting in the disintegration (dissolution) of the 3-dimensional polymer network and thereby providing mucoadhesisve polymers and optionally drugs impregnated in the hydrogel ocular insert in a controlled manner.

Abstract: A therapeutic or non-therapeutic method of inducing satiety in a mammal is described. The method comprises administering to the mammal a composition comprising microparticles, in which the microparticles comprise lipid contained within a gastric-resistant, ileal-sensitive, carrier configured for release of the lipid in the ileum, wherein the composition is administered 1-3 hours prior to a meal. The carrier is a protein, typically denatured or hydrolysed plant or dairy protein, that is polymerised to form a lipid containing shell or matrix.

Abstract: A kit for the sequential early introduction to an infant of at least two allergens to decrease the infant's risk for developing allergies, the kit including an initial lower, exposure dose of a first allergen to be taken for a day or two, a higher maintenance dose of the first allergen to be taken for several days, a maintenance dose of the first allergen and an initial lower, exposure dose of a second allergen to be taken for a day or two, and the higher maintenance dose of the first allergen and a higher maintenance does of the second allergen to be taken for several days. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula or to mother's milk. Alternatively, the allergens can already be provided in baby formula, or in other foods such as snack bars, cookies, or gels.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: The present invention relates to oral administration of water soluble cannabinoid and terpenoid concentrates on a flavored fibrous carrier. The compositions described herein provide an alternative to smoked cannabis that also avoid the slow action and unpredictable dosing of edible cannabis preparations. Water soluble concentrates of cannabinoids and terpenoids may be produced by derivatization reactions which are known in the art. Such water soluble concentrates enjoy significantly increased absorption by mucosal membranes of the mouth and may therefore be experienced by the consumer more quickly. Water soluble cannabinoid and terpenoid concentrates may be used in combination with each other and in combination with non-derivatized molecules which provides the user with fast and slow acting components in a single delivery vehicle.

Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone.

Abstract: The invention relates to dry powder compositions, suitable for inhalation through an appropriate inhalation device, comprising a thyroid hormone drug and a non-reducing sugar or sugar alcohol as a single carrier. The preparations of the invention show higher stability than the corresponding ones with lactose monohydrate, a commonly used carrier for dry powder preparations.

Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one active agent and solid particles of a diluent. The pharmaceutical composition is substantially free of excipients other than the solid diluent. The pharmaceutical composition has at least 90% of the particles of the at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of the at least one active agent with a mean particle size equal to or below 5 microns. The particles of the diluent have a mean particle size of 30-200 microns. An apparatus and method for preparation of the pharmaceutical composition utilize a spray-drying chamber, a cyclone separator, and a receiving chamber.

Abstract: The present invention provides an emulsified gel composition comprising diclofenac sodium, water, a gelling agent, an antioxidant, and a surfactant having an HLB of 14 or more, in which the gelling agent is a nonionic water-soluble polymer.

Abstract: Provided is a composition including a dispersion medium including: an aqueous solution; a first active ingredient; a flavor agent; and a first type of polymer; and a dispersed phase including: a population of particles, each particle including: a core including: a second active ingredient a second type of polymer; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a third type of polymer; a plurality of lipophilic carriers; and a third active ingredient; and a plurality of emulsifying agents.

Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.

Abstract: Accordingly, the present invention provides a pharmaceutical oil-in-water nano-emulsion, with a pharmaceutically active substance. The selected pharmaceutically active substance is encased in fatty acid (e.g., monounsaturated fatty acid, cold pressed oil, and/or esterified fatty acid) droplets with the droplets having an average particle size in the range of 10 to 200 nm. The nano-emulsion is also provided with a non-ionic surfactant system, which is a mixture of polyethers, macrogolglycerides and polysaccharides, along with pharmaceutically acceptable adjuvants. The present invention also provides a process for the preparation of pharmaceutical oil-in-water nano-emulsion.

Abstract: A submicron structure comprising a silica body defining a plurality of pores that are suitable to receive molecules therein, and having a surface, and a phospholipid bilayer coating the surface, wherein said submicron structure has a maximum dimension of less than one micron, and wherein the phospholipid bilayer stably seals the plurality of pores; and wherein the submicron structure is a member of a monodisperse population of submicron structures.

Abstract: Liposomes which comprise sphingomyelin in the lipid bilayer. The liposomes are configured to cross the blood-brain barrier for the treatment of neuro-degenerative diseases and spinal cord injuries. The liposomes are essentially free of ganglioside. A method of producing liposomes is also disclosed along with use of liposome as a medicament.

Abstract: Provided herein is a liposome comprising ribonucleic acid (RNA) molecules, a lipid mixture comprising DOTAP and cholesterol, and iron oxide nanoparticles (IONPs). Also provided herein is a liposome comprising ribonucleic acid (RNA) molecules and a lipid mixture comprising DOTAP and cholesterol, wherein the DOTAP and cholesterol are present in the lipid mixture at a DOTAP:cholesterol ratio of about 3:1 by mass. Related cells comprising the liposome, populations of cells, and compositions are also provided. Methods of making a liposome and methods of using the liposome are further provided.

Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.